| Drug Name |
Docetaxel |
| Drug ID |
BADD_D00699 |
| Description |
Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel reversibly binds to tubulin with high affinity in a 1:1 stoichiometric ratio |
| Indications and Usage |
For the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Also used as a single agent in the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. It is also used in combination with prednisone, in the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer. Furthermore, docetaxel has uses in the treatment of gastric adenocarinoma and head and neck cancer. |
| Marketing Status |
approved; investigational |
| ATC Code |
L01CD02 |
| DrugBank ID |
DB01248
|
| KEGG ID |
D02165; D07866
|
| MeSH ID |
D000077143
|
| PubChem ID |
148124
|
| TTD Drug ID |
D0O5WP
|
| NDC Product Code |
0955-1020; 43066-001; 43598-259; 0409-0367; 70121-1222; 70700-175; 68554-0075; 43598-389; 45963-765; 72485-216; 17359-9100; 43598-610; 43598-611; 47335-895; 55150-378; 57884-3041; 57884-3042; 68083-399; 68083-400; 57884-3043; 70121-1221; 72485-214; 54893-0008; 65129-1298; 16729-267; 55150-380; 62332-678; 0143-9205; 43066-006; 68083-401; 0409-4235; 70121-1223; 43066-010; 55150-379; 66758-950; 0409-0368; 70700-174; 46708-678; 47335-323; 67457-781; 0409-0366; 65129-1141; 45963-734; 0409-0365; 70700-176; 0955-1021; 65129-1189; 66758-050; 0409-5068; 72485-215; 0955-1022; 0143-9204; 43598-258; 47335-939 |
| UNII |
15H5577CQD
|
| Synonyms |
Docetaxel | Docetaxel Trihydrate | Docetaxol | Docetaxel Hydrate | Taxoltere Metro | RP 56976 | RP-56976 | RP56976 | Taxotere | Docetaxel Anhydrous | N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol | N Debenzoyl N tert butoxycarbonyl 10 deacetyltaxol | NSC 628503 |
